Sophia Archuleta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Sophia Archuleta has a total of 245 co-authors. Here are the top co-authors by number of shared publications:
- David Chien Lye
National Centre for Infectious Diseases, Singapore, Singapore
6 shared publications Halah Ibrahim
Department of Medical Science, Khalifa University College of Medicine and Health Sciences, Abu Dhabi, United Arab Emirates
5 shared publications- Shirin Kalimuddin
Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore
5 shared publications Dora J. Stadler
Department of Medicine, Weill Cornell Medical College, Doha, Qatar; Walter Reed National Military Medical Center in Bethesda, United States of America
4 shared publications- James Steven Molton
Department of Infectious Diseases, Western Health, Melbourne, Australia
4 shared publications - Ayesha J. Verrall
Department of Pathology and Molecular Medicine, University of Otago, Wellington, New Zealand
3 shared publications
Latest Publications
- 7 September 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
A Randomized Controlled Trial of Cefiderocol Versus Standard Therapy for Gram-negative Bacterial Bloodstream Infections: Benefit and Risk Assessment Using Desirability of Outcome Ranking and Generalized Pairwise Comparisons
Background: Gram-negative bacterial bloodstream infections (BSIs) cause substantial mortality and morbidity. The GAME CHANGER trial compared cefiderocol with standard of care (SOC) for Gram-negative BSIs, with 14-day all-cause mortality (ACM) as the primary endpoint. We evaluated cefiderocol versus SOC integrating efficacy and safety outcomes using desirability of outcome ranking (DOOR) and generalized pairwise comparisons (GPC). Methods: Composite endpoints were prespecified before data review. The DOOR endpoint included treatment failure, infectious complications, serious adverse events, and 90-day ACM, with functional improvement as a tiebreaker. The GPC approach included ACM at 30 days, clinical failure, serious adverse events, functional improvement, and hospitalization duration. Analyses were conducted in the main population and carbapenem-resistant subset. Results: The DOOR composite in the main population resulted in a probability of a more desirable outcome with cefiderocol of 50.4% (95% confidence interval [CI], 45.6–55.1). The analysis with GPC resulted in a win ratio and win odds of 1.04 (95% CI, 0.85–1.28) and net treatment benefit of 2.1% (95% CI, −8.0 to 12.2). In the carbapenem-resistant subset, the DOOR probability with cefiderocol was 46.8% (95% CI, 37.4–56.1). The analysis with GPC resulted in a win ratio and win odds of 0.90 (95% CI, 0.60–1.34) and net treatment benefit of −5.4% (95% CI, −25.3 to 14.5). Conclusions: In adults with Gram-negative bacterial BSIs, cefiderocol was not superior to SOC based on DOOR or GPC analyses in both the main population and carbapenem-resistant subset. Integrating efficacy, safety, and functional outcomes using these approaches provides a more comprehensive assessment than mortality alone.
- 7 September 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
A Randomized Controlled Trial of Cefiderocol Versus Standard Therapy for Gram-negative Bacterial Bloodstream Infections: Benefit and Risk Assessment Using Desirability of Outcome Ranking and Generalized Pairwise Comparisons
Background: Gram-negative bacterial bloodstream infections (BSIs) cause substantial mortality and morbidity. The GAME CHANGER trial compared cefiderocol with standard of care (SOC) for Gram-negative BSIs, with 14-day all-cause mortality (ACM) as the primary endpoint. We evaluated cefiderocol versus SOC integrating efficacy and safety outcomes using desirability of outcome ranking (DOOR) and generalized pairwise comparisons (GPC). Methods: Composite endpoints were prespecified before data review. The DOOR endpoint included treatment failure, infectious complications, serious adverse events, and 90-day ACM, with functional improvement as a tiebreaker. The GPC approach included ACM at 30 days, clinical failure, serious adverse events, functional improvement, and hospitalization duration. Analyses were conducted in the main population and carbapenem-resistant subset. Results: The DOOR composite in the main population resulted in a probability of a more desirable outcome with cefiderocol of 50.4% (95% confidence interval [CI], 45.6–55.1). The analysis with GPC resulted in a win ratio and win odds of 1.04 (95% CI, 0.85–1.28) and net treatment benefit of 2.1% (95% CI, −8.0 to 12.2). In the carbapenem-resistant subset, the DOOR probability with cefiderocol was 46.8% (95% CI, 37.4–56.1). The analysis with GPC resulted in a win ratio and win odds of 0.90 (95% CI, 0.60–1.34) and net treatment benefit of −5.4% (95% CI, −25.3 to 14.5). Conclusions: In adults with Gram-negative bacterial BSIs, cefiderocol was not superior to SOC based on DOOR or GPC analyses in both the main population and carbapenem-resistant subset. Integrating efficacy, safety, and functional outcomes using these approaches provides a more comprehensive assessment than mortality alone.
- Open Access
- 30 April 2026
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 169, 108750
Real-world outcomes of a complex outpatient oral antimicrobial therapy (COpAT) clinic for deep-seated infections in Singapore
- 30 April 2026
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 169, 108750
Open AccessReal-world outcomes of a complex outpatient oral antimicrobial therapy (COpAT) clinic for deep-seated infections in Singapore
- Open Access
- 17 March 2026
- Published by Springer Nature in AIDS and Behavior
- Vol. 30 (10) , 1-10
Perspectives on Analytical Treatment Interruptions and Prospects of an HIV Cure Amongst People Living with HIV and Healthcare Providers in Singapore
Singapore has yet to conduct an HIV cure trial, and analytical treatment interruption (ATI) studies may face community scepticism. This study explores the perspectives of people living with HIV and healthcare providers in Singapore on participating in functional cure research involving ATI. Participants were recruited from four HIV care facilities through study advertisements. Healthcare providers were recruited via email. A self-administered survey gathered demographic data, views on ATI and HIV cure, acceptability of ATI, and tolerance for CD4 and viral load changes during ATI. Descriptive, univariate, and multivariable logistic regression analyses were used to identify barriers and motivators to trial participation. Among 200 people living with HIV, 116 (58%) expressed willingness to participate in a cure trial; 84 (42%) did not. Most (94.5%, 189/200) had never joined an HIV clinical study. No significant differences in age, gender, sexuality, or HIV duration were observed between the groups. Factors positively associated with willingness to participate included tertiary education (aOR 2.71, 95% CI 1.13–6.81), altruistic motivations (aOR 1.98, 95% CI 1.52–2.66), and financial compensation (aOR 3.55, 95% CI 1.36–9.88). Lower tolerance for viral load increases or CD4 declines was linked to reduced willingness (aOR 0.77, 95% CI 0.67–0.88). Monitoring frequency, self-testing, and home visits had no significant effect. Healthcare providers were more likely to recommend participation in cure trials if they demonstrated high tolerance for HIV viral load increases (p = 0.044), showed stronger interest in cure research (p = 0.009) and expressed greater acceptance of a functional HIV cure (p = 0.014). Willingness to participate in ATI cure trials is higher among individuals with more education, altruistic intent, and less concern about virologic or immunologic changes. Financial compensation is a strong motivating factor but should not play undue inducement in influencing decision to participate in an ATI cure trial. Community engagement and education are crucial to building support for future HIV cure research.
- 17 March 2026
- Published by Springer Nature in AIDS and Behavior
- Vol. 30 (10) , 1-10
Open AccessPerspectives on Analytical Treatment Interruptions and Prospects of an HIV Cure Amongst People Living with HIV and Healthcare Providers in Singapore
Singapore has yet to conduct an HIV cure trial, and analytical treatment interruption (ATI) studies may face community scepticism. This study explores the perspectives of people living with HIV and healthcare providers in Singapore on participating in functional cure research involving ATI. Participants were recruited from four HIV care facilities through study advertisements. Healthcare providers were recruited via email. A self-administered survey gathered demographic data, views on ATI and HIV cure, acceptability of ATI, and tolerance for CD4 and viral load changes during ATI. Descriptive, univariate, and multivariable logistic regression analyses were used to identify barriers and motivators to trial participation. Among 200 people living with HIV, 116 (58%) expressed willingness to participate in a cure trial; 84 (42%) did not. Most (94.5%, 189/200) had never joined an HIV clinical study. No significant differences in age, gender, sexuality, or HIV duration were observed between the groups. Factors positively associated with willingness to participate included tertiary education (aOR 2.71, 95% CI 1.13–6.81), altruistic motivations (aOR 1.98, 95% CI 1.52–2.66), and financial compensation (aOR 3.55, 95% CI 1.36–9.88). Lower tolerance for viral load increases or CD4 declines was linked to reduced willingness (aOR 0.77, 95% CI 0.67–0.88). Monitoring frequency, self-testing, and home visits had no significant effect. Healthcare providers were more likely to recommend participation in cure trials if they demonstrated high tolerance for HIV viral load increases (p = 0.044), showed stronger interest in cure research (p = 0.009) and expressed greater acceptance of a functional HIV cure (p = 0.014). Willingness to participate in ATI cure trials is higher among individuals with more education, altruistic intent, and less concern about virologic or immunologic changes. Financial compensation is a strong motivating factor but should not play undue inducement in influencing decision to participate in an ATI cure trial. Community engagement and education are crucial to building support for future HIV cure research.
- Open Access
HIV—Now Another Long Term Chronic Condition?
Over the past 25 years, with advances in treatment, HIV infection has become a manageable, chronic illness. In patients who manage their treatment carefully, they can expect almost normal lifespans, similar to other chronic diseases like diabetes. This article briefly summarizes ongoing risks to people living with HIV, highlighting the need to adhere to therapy and monitoring for possible long-term complications and adverse effects in the context of other common systemic illnesses.
Open AccessHIV—Now Another Long Term Chronic Condition?
Over the past 25 years, with advances in treatment, HIV infection has become a manageable, chronic illness. In patients who manage their treatment carefully, they can expect almost normal lifespans, similar to other chronic diseases like diabetes. This article briefly summarizes ongoing risks to people living with HIV, highlighting the need to adhere to therapy and monitoring for possible long-term complications and adverse effects in the context of other common systemic illnesses.
- Open Access
- 28 July 2025
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 67, 102882
Redefining outpatient dengue management 18 years on: lessons from a national tertiary centre
- 28 July 2025
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 67, 102882
Open AccessRedefining outpatient dengue management 18 years on: lessons from a national tertiary centre
- 13 November 2024
- Published by Oxford University Press (OUP) in Academic Medicine
- Vol. 100 (3) , 259-260
Accreditation Scholarship in International Medical Education
An abstract is unavailable. This article is available as a PDF only.
- 13 November 2024
- Published by Oxford University Press (OUP) in Academic Medicine
- Vol. 100 (3) , 259-260
Accreditation Scholarship in International Medical Education
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 1 October 2024
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (10) , e2439932
Open Access Publishing Metrics, Cost, and Impact in Health Professions Education Journals
Importance: Publishing in health professions education (HPE) journals is an integral component of academic discourse and career progression. Research in this field is shifting to an open access (OA) publishing model.Objective: To identify the characteristics and publishing models of HPE journals and explore potential associations between publication costs and journal metrics.Design, Setting, and Participants: This cross-sectional study was conducted between September 20, 2023, and February 14, 2024, using the World Bank purchasing power parity (PPP) index to analyze relative costs of article processing charges (APCs). Data on journal characteristics, impact metrics, APCs, and waiver or discount were extracted from the National Library of Medicine, Scimago, Scopus, journal websites, and email correspondence with editorial staff of journals. All HPE journals indexed in PubMed, written in or translated into English, and with HPE as a core component of their mission were included in the analysis.Main Outcomes and Measures: Two-year impact factor, H-index, cite score, Scientific Journal Ranking, and APC.Results: Among the 51 journals included, 27 (53%) adopted OA-only and 24 (47%) adopted hybrid publishing models. The median (IQR) APC for all journals was $2820.00 ($928.00-$3300.00). Associations were observed between impact factor and APC (β coefficient, $386.84; 95% CI, $226.84-$546.84; P < .001) and between cite score and APC (β coefficient, $282.40; 95% CI, $148.12-$416.61; P < .001). Of 20 journal websites with information regarding fee waivers or discounts, 7 journals (35%) confirmed fee waiver or discount. The PPP index analysis of the top 39 countries publishing HPE research showed that the financial burden of meeting the median APC for publication was 1.94 to 10.26 times higher for authors from lower-income countries than for authors from the US.Conclusions and Relevance: Results of this cross-sectional study suggest that adoption by HPE journals of an OA publishing model was high but access to APC waivers or discounts was limited. These factors create barriers to equitable OA practices, necessitating concerted efforts, such as increasing transparency of publishing costs, implementing economic impact analysis, expanding waivers to eligible authors, and applying holistic impact factor scoring.
- 1 October 2024
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (10) , e2439932
Open AccessOpen Access Publishing Metrics, Cost, and Impact in Health Professions Education Journals
Importance: Publishing in health professions education (HPE) journals is an integral component of academic discourse and career progression. Research in this field is shifting to an open access (OA) publishing model.Objective: To identify the characteristics and publishing models of HPE journals and explore potential associations between publication costs and journal metrics.Design, Setting, and Participants: This cross-sectional study was conducted between September 20, 2023, and February 14, 2024, using the World Bank purchasing power parity (PPP) index to analyze relative costs of article processing charges (APCs). Data on journal characteristics, impact metrics, APCs, and waiver or discount were extracted from the National Library of Medicine, Scimago, Scopus, journal websites, and email correspondence with editorial staff of journals. All HPE journals indexed in PubMed, written in or translated into English, and with HPE as a core component of their mission were included in the analysis.Main Outcomes and Measures: Two-year impact factor, H-index, cite score, Scientific Journal Ranking, and APC.Results: Among the 51 journals included, 27 (53%) adopted OA-only and 24 (47%) adopted hybrid publishing models. The median (IQR) APC for all journals was $2820.00 ($928.00-$3300.00). Associations were observed between impact factor and APC (β coefficient, $386.84; 95% CI, $226.84-$546.84; P < .001) and between cite score and APC (β coefficient, $282.40; 95% CI, $148.12-$416.61; P < .001). Of 20 journal websites with information regarding fee waivers or discounts, 7 journals (35%) confirmed fee waiver or discount. The PPP index analysis of the top 39 countries publishing HPE research showed that the financial burden of meeting the median APC for publication was 1.94 to 10.26 times higher for authors from lower-income countries than for authors from the US.Conclusions and Relevance: Results of this cross-sectional study suggest that adoption by HPE journals of an OA publishing model was high but access to APC waivers or discounts was limited. These factors create barriers to equitable OA practices, necessitating concerted efforts, such as increasing transparency of publishing costs, implementing economic impact analysis, expanding waivers to eligible authors, and applying holistic impact factor scoring.
- 31 July 2024
- Published by SAGE Publications in Trauma, Violence, & Abuse
- Vol. 25 (5) , 3843-3871
Microaggression Interactions Among Healthcare Professionals, Trainees and Students in the Clinical Environment: A Mixed-Studies Review
This review aims to comprehensively consolidate and synthesize the existing body of empirical research on the perceptions and experiences of healthcare professionals, trainees, and students concerning microaggression interactions within diverse clinical settings. The review protocol was registered with the international prospective register of systematic reviews (PROSPERO CRD42024546443). We employed the Joanna Briggs Institute’s mixed-methods systematic review approach. Comprehensive electronic database searches were conducted across eight databases (Medline, Embase, CINAHL, PsycINFO, Scopus, Web of Science, Social Science Database, and ProQuest Dissertation and Theses) from their respective inception dates up to October 1, 2023. The selection criteria included studies reporting instances of interprofessional or intra-professional microaggressions occurring in clinical environments among healthcare professionals, trainees, and students identifying as heterosexual and without disabilities. In total, 37 studies met the eligibility criteria and were included in our review. Our analysis revealed three primary themes: Racial Microaggressions in the Clinical Environment, Gender Microaggressions in the Clinical Environment, and Religious Microaggressions in the Clinical Environment. Research must delve deeply into these experiences to better understand their long-term consequences, while policy initiatives should be designed to establish equitable, inclusive, and respectful healthcare environments. Collaborative endeavors bridging research and policy are paramount to dismantling barriers and nurturing an inclusive healthcare landscape.
- 31 July 2024
- Published by SAGE Publications in Trauma, Violence, & Abuse
- Vol. 25 (5) , 3843-3871
Microaggression Interactions Among Healthcare Professionals, Trainees and Students in the Clinical Environment: A Mixed-Studies Review
This review aims to comprehensively consolidate and synthesize the existing body of empirical research on the perceptions and experiences of healthcare professionals, trainees, and students concerning microaggression interactions within diverse clinical settings. The review protocol was registered with the international prospective register of systematic reviews (PROSPERO CRD42024546443). We employed the Joanna Briggs Institute’s mixed-methods systematic review approach. Comprehensive electronic database searches were conducted across eight databases (Medline, Embase, CINAHL, PsycINFO, Scopus, Web of Science, Social Science Database, and ProQuest Dissertation and Theses) from their respective inception dates up to October 1, 2023. The selection criteria included studies reporting instances of interprofessional or intra-professional microaggressions occurring in clinical environments among healthcare professionals, trainees, and students identifying as heterosexual and without disabilities. In total, 37 studies met the eligibility criteria and were included in our review. Our analysis revealed three primary themes: Racial Microaggressions in the Clinical Environment, Gender Microaggressions in the Clinical Environment, and Religious Microaggressions in the Clinical Environment. Research must delve deeply into these experiences to better understand their long-term consequences, while policy initiatives should be designed to establish equitable, inclusive, and respectful healthcare environments. Collaborative endeavors bridging research and policy are paramount to dismantling barriers and nurturing an inclusive healthcare landscape.
- Open Access
- 1 July 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (7) , ofad337
Longer-term Mortality and Kidney Outcomes of Participants in the Combination Antibiotics for Methicillin-Resistant Staphylococcus aureus (CAMERA2) Trial: A Post Hoc Analysis
The Combination Antibiotic Therapy for Methicillin-Resistant Staphylococcus aureus (CAMERA2) trial ceased recruitment in July 2018, noting that a higher proportion of patients in the intervention arm (combination therapy) developed acute kidney injury (AKI) compared to the standard therapy (monotherapy) arm. We analyzed the long-term outcomes of participants in CAMERA2 to understand the impact of combination antibiotic therapy and AKI. Trial sites obtained additional follow-up data. The primary outcome was all-cause mortality, censored at death or the date of last known follow-up. Secondary outcomes included kidney failure or a reduction in kidney function (a 40% reduction in estimated glomerular filtration rate to 2). To determine independent predictors of mortality in this cohort, adjusted hazard ratios were calculated using a Cox proportional hazards regression model. This post hoc analysis included extended follow-up data for 260 patients. Overall, 123 of 260 (47%) of participants died, with a median population survival estimate of 3.4 years (235 deaths per 1000 person-years). Fifty-five patients died within 90 days after CAMERA2 trial randomization; another 68 deaths occurred after day 90. Using univariable Cox proportional hazards regression, mortality was not associated with either the assigned treatment arm in CAMERA2 (hazard ratio [HR], 0.84 [95% confidence interval [CI], .59–1.19]; P = .33) or experiencing an AKI (HR at 1 year, 1.04 [95% CI, .64–1.68]; P = .88). In this cohort of patients hospitalized with methicillin-resistant S aureus bacteremia, we found no association between either treatment arm of the CAMERA2 trial or AKI (using CAMERA2 trial definition) and longer-term mortality.
- 1 July 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (7) , ofad337
Open AccessLonger-term Mortality and Kidney Outcomes of Participants in the Combination Antibiotics for Methicillin-Resistant Staphylococcus aureus (CAMERA2) Trial: A Post Hoc Analysis
The Combination Antibiotic Therapy for Methicillin-Resistant Staphylococcus aureus (CAMERA2) trial ceased recruitment in July 2018, noting that a higher proportion of patients in the intervention arm (combination therapy) developed acute kidney injury (AKI) compared to the standard therapy (monotherapy) arm. We analyzed the long-term outcomes of participants in CAMERA2 to understand the impact of combination antibiotic therapy and AKI. Trial sites obtained additional follow-up data. The primary outcome was all-cause mortality, censored at death or the date of last known follow-up. Secondary outcomes included kidney failure or a reduction in kidney function (a 40% reduction in estimated glomerular filtration rate to 2). To determine independent predictors of mortality in this cohort, adjusted hazard ratios were calculated using a Cox proportional hazards regression model. This post hoc analysis included extended follow-up data for 260 patients. Overall, 123 of 260 (47%) of participants died, with a median population survival estimate of 3.4 years (235 deaths per 1000 person-years). Fifty-five patients died within 90 days after CAMERA2 trial randomization; another 68 deaths occurred after day 90. Using univariable Cox proportional hazards regression, mortality was not associated with either the assigned treatment arm in CAMERA2 (hazard ratio [HR], 0.84 [95% confidence interval [CI], .59–1.19]; P = .33) or experiencing an AKI (HR at 1 year, 1.04 [95% CI, .64–1.68]; P = .88). In this cohort of patients hospitalized with methicillin-resistant S aureus bacteremia, we found no association between either treatment arm of the CAMERA2 trial or AKI (using CAMERA2 trial definition) and longer-term mortality.
- 23 May 2023
- Published by Oxford University Press (OUP) in Academic Medicine
- Vol. 98 (9) , 974
Women Physicians Group to Mitigate Bullying in International Academic Medicine
An abstract is unavailable. This article is available as a PDF only.
- 23 May 2023
- Published by Oxford University Press (OUP) in Academic Medicine
- Vol. 98 (9) , 974
Women Physicians Group to Mitigate Bullying in International Academic Medicine
An abstract is unavailable. This article is available as a PDF only.